Interleukin 38 as a Biomarker for Metabolic Syndrome in Psoriatic Patients
- Conditions
- Psoriasis
- Registration Number
- NCT05076812
- Lead Sponsor
- Sohag University
- Brief Summary
case control study to compare level of interleukin 38 in patients with psoriasis and patients with metabolic syndrome with healthy control subjects
- Detailed Description
this case control study will measure plasma level of interleukin 38 in 4 groups of 24 subject, group one will have psoriatic patients, group 2 will have psoriatic patients with metabolic syndrome, group three will have patients with metabolic syndrome only, and group 4 will have healthy control subjects.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 96
Inclusion Criteria
- specific to each group
Exclusion Criteria
- Patient refusal. Age <18 years Pregnancy Lactation smoking Infections. Patients with other inflammatory skin disorders use of antioxidant and anti-inflammatory drugs patients on treatment for psoriasis
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method measure plasma level of interleukin 38 in all groups through study completion an average of 18 months level of interleukin 38 will be measured and compared in all groups to asses the relationship between this interleukin and metabolic syndrome in psoriatic patients
- Secondary Outcome Measures
Name Time Method